We are live on ! Find out more
TBIO

Translate Bio, Inc. Common Stock
TBIO

Delisted

TBIO was delisted on the 13th of September, 2021.

0 hedge funds and large institutions have $0 invested in Translate Bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 145 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,500% more call options, than puts

Call options by funds: $104K | Put options by funds: $4K

100% less funds holding

Funds holding: 1450 (-145)

100% less funds holding in top 10

Funds holding in top 10: 40 (-4)

100% less capital invested

Capital invested by funds: $1.85B → $0 (-$1.85B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 145

Holders
Holders Change
-145
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
New
Increased
Reduced
Closed
145
Calls
$104K
Puts
$4K
Net Calls
+$100K
Net Calls Change
+$179K

TBIO Hedge Fund Activity: Q3 2021 in Review

0 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Translate Bio, Inc. Common Stock (TBIO) for Q3 2021, worth a combined $0 — down 100% from $1.85B a quarter earlier.

Sellers outnumbered buyers: 145 funds closed out of TBIO and 0 opened new positions — a net loss of 145 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baupost Group, exiting entirely with an estimated $494M sold.

  • 0 institutional investors held Translate Bio, Inc. Common Stock (TBIO) as of Q3 2021, down from 145 in Q2 2021.
  • Funds reported $0 of Translate Bio, Inc. Common Stock stock for Q3 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Translate Bio, Inc. Common Stock positions in Q3 2021 and 145 closed out, a net change of -145 holders.
  • The largest Translate Bio, Inc. Common Stock seller in Q3 2021 was Baupost Group, an estimated $494M sold.

Based on aggregated 13F filings for Q3 2021.